SAN FRANCISCO – Six abstracts exploring key issues in the treatment of gastrointestinal cancers will be presented at the 2017 Gastrointestinal Cancers Symposium, taking place January 19-21 at the Moscone West Building in San Francisco.
ALEXANDRIA, Va. – Findings from a federally funded clinical trial point to a new way to improve the outlook for patients with esophageal cancer: using PET scans to assess tumor response to initial chemotherapy may allow doctors to tailor further chemotherapy. Despite aggressive combined modality treatment with chemotherapy, radiation therapy, and surgery, the prognosis for patients with esophageal cancer is poor, with fewer than 50% surviving at five years after diagnosis. Ways to monitor treatment effectiveness are urgently needed to improve outcomes. The study will be presented at the upcoming 2017 Gastrointestinal Cancers Symposium in San Francisco.
ALEXANDRIA, Va. – A new analysis suggests that people with metastatic colorectal cancer who are more physically active fare better than those who are less active. In a large clinical trial, patients who at the time of starting chemotherapy reported engaging in physical activity equivalent to 30 or more minutes of moderate exercise daily had a 19% reduction in mortality and a 16% reduction in cancer progression. The study will be presented at the upcoming 2017 Gastrointestinal Cancers Symposium in San Francisco.
ALEXANDRIA, Va. – Real-world data from a large observational study suggests that omitting surgery in strictly selected patients with a clinical complete response does not compromise outcomes. The three-year survival rate among patients who received “watch-and-wait” care after initial cancer treatment was 91%, which is similar to historic survival rates for patients who undergo surgery. This is welcome news, as rectal surgery carries the risk of debilitating complications, such as colostomy and urinary and sexual problems. The study will be presented at the upcoming 2017 Gastrointestinal Cancers Symposium in San Francisco.
Alexandria, Va. – The American Society of Clinical Oncology (ASCO) released, “ASCO Principles for Patient-Centered Healthcare Reform,” seven recommendations designed to ensure access to high-quality cancer care amid the changing U.S. healthcare delivery landscape. The principles aim to assist the new Congress and Administration, so, as they consider the critical underpinnings of any healthcare reform proposal, the needs of patients facing a cancer diagnosis are met.
ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that George A. Komatsoulis, Ph.D., will be its first Chief of Bio-Informatics. This marks another step toward the organization's goal of making the CancerLinQ® platform the premier system for unlocking patient data from millions of electronic health records (EHR), breaking down silos among various EHR systems and providers, and securely processing and analyzing the data to give personalized insights than can improve the quality of care for patients with cancer.
Alexandria, Va. – CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology® (ASCO), today announced CancerLinQ Discovery™, a groundbreaking offering that will provide insights through the analysis of real-world cancer care data. CancerLinQ Discovery will provide highly curated, de-identified sets of clinical data with the objective of creating new clinical knowledge and improving patient outcomes. It will derive these sets from the rapidly-growing CancerLinQ® database, which now includes over 1.5 million patient records and more than 70 oncology practices that have agreed to contribute data to CancerLinQ’s core quality improvement and data-sharing platform.
More than 100 participants are now enrolled on study drug in the American Society of Clinical Oncology’s (ASCO®) Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The trial launched in March 2016 at 37 sites and this month welcomes its newest participating clinical sites: Cancer Treatment Centers of America®, Intermountain Healthcare, Sanford Health, Swedish Cancer Institute and Providence Health & Services, and University of Nebraska Medical Center for a total of 63 participating sites in 15 states.
ALEXANDRIA, VA – A new collaboration between the American Society of Clinical Oncology (ASCO) and the American Board of Internal Medicine (ABIM) will enable participants of ASCO’s Quality Oncology Practice Initiative (QOPI®) and the QOPI Certification Program (QCP) to receive Maintenance of Certification (MOC) Practice Assessment points from ABIM.
ALEXANDRIA, Va. – CancerLinQ LLC, a wholly-owned nonprofit of the American Society of Clinical Oncology (ASCO), announced today that more than one million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ, representing more than 1,500 oncologists.
ALEXANDRIA, Va. – CancerLinQ LLC (CLQ LLC) CEO Kevin Fitzpatrick has been appointed to the Cancer Informatics for Cancer Centers (CI4CC) Corporate Advisory Board. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, Inc. (ASCO®) and Mr. Fitzpatrick’s appointment builds on CI4CC and CLQ LLC’s collaborative efforts to help improve cancer care.
The American Society of Clinical Oncology (ASCO) announced today the 14 practices participating in the 2016 Quality Training Program. The program is designed to train oncology health care providers to investigate and implement data-driven quality improvement and manage clinical and administrative processes and outcomes.
The American Society of Clinical Oncology (ASCO) and CancerLinQ LLC will join Vice President Joe Biden and other leaders in the cancer community for the Cancer Moonshot Summit at Howard University, on June 29, to launch new collaborations and exchange ideas on solving the complexities of cancer care.
The American Society of Clinical Oncology (ASCO) announced today that Bayer and Merck are the most recent companies to sign on to provide study drugs at no cost to patients enrolled in the Targeted Agent and Profiling Utilization Registry (TAPUR) study, joining six other companies in ASCO’s first-ever clinical trial. Since opening on March 14, 2016, 18 participants have enrolled and are receiving study treatment, and 31 more have provided consent and are in, or have completed, the screening process. These numbers continue to grow daily.
CHICAGO – A randomized phase III clinical trial, MA.17R found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor (AI) therapy with letrozole (Femara) from 5 to 10 years. Following five years of an AI and any duration of prior tamoxifen, women who received letrozole for five additional years had a 34% lower risk of recurrence than those who received placebo. The trial was led by the Canadian Cancer Trials Group with participation from the National Clinical Trials Network.